ENOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension

Pharmacogenomics Journal

Volumn 10, Issue 1, 2010, Pages 40-45

  Sandrim, V C ^a,b   Palei, A C T ^c   Luizon, M R ^b   Izidoro Toledo, T C ^b   Cavalli, R C ^b   Tanus Santos, J E ^b  

^a Santa Casa de Belo Horizonte   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antihypertensives; ENOS; Gestational hypertension; Pharmacogenetics; Polymorphisms; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; ASPARTIC ACID; CYTOSINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTAMIC ACID; HYDRALAZINE; METHYLDOPA; NIFEDIPINE; THYMINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PHARMACOGENETICS; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 75549085532     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.38     Document Type: Article

References (38)

1. Anonymous. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
2. Sibai BM. Intergenerational factors. A missing link for preeclampsia, fetal growth restriction, and cardiovascular disease? Hypertension 2008; 7: 7.
3. Walker JJ. Pre-eclampsia. Lancet 2000; 356: 1260-1265.
4. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-1249.
5. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51: 960-969.
6. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007; 196: 514.
7. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 2006; 8(12 Suppl 4): 2-16.
8. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 265-284. (Pubitemid 34169434)
9. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714.
10. Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272 (2 Pt 2): H748-H752.
11. Weiner CP, Knowles RG, Moncada S. Induction of nitric oxide synthases early in pregnancy. Am J Obstet Gynecol 1994; 171: 838-843.
12. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008; 52: 402-407.
13. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994; 171: 944-948.
14. Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Ann Clin Lab Sci 2002; 32: 257-263.
15. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-725.
16. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G et al. eNOS haplotypes associated with gestational hypertension or pre-eclampsia. Pharmacogenomics 2008; 9: 1467-1473.
17. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 2006; 186: 428-432.
18. Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 2006; 189: 241-246.
19. Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno Jr H, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 2006; 24: 2393-2397.
20. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med 2005; 56: 303-320.
21. de Vasconcelos D, Izidoro-Toledo TC, Sandrim VC, Tanus-Santos JE, Palei AC, Cavalli RC. Aldosterone synthase gene polymorphism is not associated with gestational hypertension or preeclampsia. Clin Chim Acta 2009; 400: 139-141.
22. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
23. Metzger IF, Sertorio JT, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 2007; 43: 987-992.
24. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 2005; 15: 565-570.
25. Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE. Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 2007; 16: 348-355.
26. Serrano NC, Casas JP, Diaz LA, Paez C, Mesa CM, Cifuentes R et al. Endothelial NO synthase genotype and risk of preeclampsia: a multi-center case-control study. Hypertension 2004; 44: 702-707. Epub 2004 Sep 2013.
27. Nagassaki S, Herculano RD, Graeff CF, Tanus-Santos JE. eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol 2009; 65: 385-392.
28. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 2006; 41: 1044-1049.
29. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007; 193: 438-444.
30. Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002; 12: 407-413.
31. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Cardiac Failure 2009; 15: 191-198.
32. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943-948.
33. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 2000; 292: 606-609.
34. Lopez-Jaramillo P, Narvaez M, Calle A, Rivera J, Jacome P, Ruano C et al. Cyclic guanosine 3',5' monophosphate concentrations in pre-eclamp-sia: effects of hydralazine. Br J Obstet Gynaecol 1996; 103: 33-38.
35. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007: CD002252.
36. von Dadelszen P, Magee LA. Antihypertensive medications in management of gestational hypertension-preeclampsia. Clin Obstet Gynecol 2005; 48: 441-459.
37. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
38. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 2005; 12: 177-182.